TORONTO, April 5, 2016 /CNW Telbec/ - As part of its
ongoing commitment to education, Bedrocan Canada Inc. (Bedrocan
Canada) will host its inaugural Masterclass course for medical
professionals on Saturday, May 14th,
2016. The renowned Masterclass program was developed in
the Netherlands by Bedrocan BV and
continues to attract participants from around the world each year.
This is the first time that the in-depth seminar is being offered
to Canadian physicians.
Our one-day Masterclass will explore medical cannabis from a
practitioner's perspective, offering participants a number of
detailed lectures, practical demonstrations, and a tour of Bedrocan
Canada's facility. The Masterclass will offer a unique perspective
into all facets of cannabinoid medicine, from chemistry and quality
assurance, to patient care and safe consumption.
"It's important that healthcare practitioners have the
opportunity to learn about cannabis from a medical and patient
perspective, so they can make informed decisions," said
Amanda Daley, Head of Medical
Education and Outreach at Bedrocan Canada. "As more patients become
interested in cannabis as a treatment for a variety of symptoms,
doctors will need to be able to answer cannabis-related questions
when their patients bring them up. The Masterclass is a unique
opportunity for practitioners to learn from leaders in the
field."
Twenty-five healthcare practitioners will participate. One major
aim of the Masterclass is to bring together individuals from
diverse fields and specialties. Interested candidates are invited
to submit a brief motivation letter to masterclass@bedrocan.ca by
April 22nd.
Bedrocan Canada is dedicated to its strong roots in the medical
sector, and the Masterclass is the next step in a series of
Bedrocan Canada initiatives that focus on advancing the field of
cannabinoid medicine.
Presenters:
Dr. Arno Hazekamp, Head of
Research and Education at Bedrocan BV, will offer his expertise in
all facets of a science-based approach to medical cannabis. His
first seminar will discuss the chemical properties of cannabis,
providing a basis for understanding cannabinoids and terpenes as
well as the body's own endocannabionids. Dr. Hazekamp will also
conduct a seminar on administration forms, quality control, and
product development. Dr. Hazekamp was actively involved in creating
quality standards used by the Dutch Government, and was a
co-founder of the non-governmental organization (NGO) NCSM,
intended to inform physicians and patients of the proper use of
cannabis in clinical practice.
He is the author of numerous scientific papers on cannabis
chemistry, delivery mechanisms, quality control and patient
surveys. As an international authority on biochemical cannabis
research, he is considered one of the foremost researchers in the
field.
Dr. Danial Schecter, the
co-founder of the Cannabinoid Medical Clinic (CMClinic), a
practicing family physician and leader in the field of cannabinoid
medicine, will discuss his approach to prescribing, the patient
perspective, and safe cannabis consumption in his clinical seminar.
After working alongside some of Canada's leading researchers in the field of
medical cannabis, Dr. Schecter developed a strong interest in the
therapeutic use of cannabinoids. As a recognized medical expert in
the field of prescription cannabinoids and medical cannabis, Dr.
Schecter has given numerous presentations to fellow physicians and
developed educational programs on this subject.
Tjalling Erkelens, the CEO and
Founder of Bedrocan BV, will discuss the finer points of
standardization, growing, and cannabis varieties. For the
past 20 years, Mr. Erkelens has developed and standardized methods
of producing cannabis to medical grade. Under his leadership,
Bedrocan BV has become the only company in the world whose cannabis
is exported for patient use in full compliance with international
law. Bedrocan BV currently supplies cannabis to patients in
Czech Republic, Germany, Italy, Finland, Poland and Norway, and to researchers around the
world.
About Bedrocan Canada
Bedrocan Canada is focused on medical cannabis production and
research, including the EQUAL Study, which is currently enrolling
patients and evaluating how cannabis is affecting the quality of
life of Canadian patients. Bedrocan's standardized strains have
been used by tens of thousands of patients in seven countries
around the world. www.bedrocan.ca
About Bedrocan BV
Bedrocan® BV has its roots in the agricultural sector of the
northern Netherlands and is the
only producer of medicinal cannabis for the Dutch Ministry of
Health. The cannabis is produced to the highest quality
standards, in compliance with national and international regulatory
requirements. It has been sold in pharmacies on prescription since
2003, covered by health insurance in the Netherlands since 2011, and is the only
cannabis in the world exported for medical use.
About Canopy Growth Corporation
Canopy Growth is Canada's first publicly traded medical
cannabis company and the first geographically diversified producer
with multiple licenses under the Marihuana for Medical Purposes
Regulations. Through its wholly owned subsidiaries, Tweed, Tweed
Farms, and Bedrocan Canada, the Company operates three
state-of-the-art production facilities in Ontario and
distributes cannabis across the country to Canadian patients
managing a host of medical conditions. The Company is dedicated to
educating healthcare practitioners, providing consistent access to
high quality medication, conducting robust clinical research, and
furthering the public's understanding of how cannabis is used for
medical purposes. www.canopygrowth.com.
Forward Looking Statement
This news release contains forward-looking statements. Often,
but not always, forward-looking statements can be identified by the
use of words such as "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company or any of its
subsidiaries to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements.
Although Canopy Growth Corporation has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results not to be as anticipated, estimated or
intended. Readers should not place undue reliance on
forward-looking statements. The factors identified above are not
intended to represent a complete list of the factors that could
affect the Company or any of its subsidiaries. The forward-looking
statements included in this news release are made as of the date of
this news release and Canopy Growth Corporation does not undertake
an obligation to publicly update such forward-looking statements to
reflect new information, subsequent events or otherwise unless
required by applicable securities legislation.
SOURCE Canopy Growth Corporation